GSK wins approval from the U.S. FDA for shingles vaccine

Date: 2017-10-24   Author: Pankaj Singh  Category: #market

GSK wins approval from the U.S. FDA for shingles vaccine

GlaxoSmithKline (GSK) PLC, the British pharma giant, has apparently received the awaited green signal from the U.S. Food and Drug Administration for its new and enhanced shingles vaccine. As per reports, the Brentford-based joint venture is also hoping to win approval for another of its key products this year.

Sources claim that GSK’s shingles vaccine stood better than Zostavax, a product of Merck & Co, in the clinical trials carried out by the FDA. The fact that Shingrix - GSK’s shingles vaccine, has been approved by the FDA is one of the important acquittals of the company’s product pipeline. The vaccine is touted to emerge as one of most pivotal products in GSK’s portfolio, and has been claimed by analysts to collect a revenue of USD 1.36 billion by the end of 2023.

A month prior to the shingles vaccine approval, GSK made it to the headlines for having received the green signal for its three-in-one inhaler, designed to be used in chronic lung disease treatment. Post a series of approvals, further on, GSK hopes to launch a dual regimen drug for HIV. The U.S. regulatory bodies are apparently planning to carry out clinical trials for this groundbreaking drug regimen by the end of 2017.

Currently, it is being reported that Shingrix and Zostavax are the only available vaccines for shingles prevention, though the former has been declared to be more effective. Apart from the FDA, an advisory committee of the United States Centers for Disease Control and Prevention on immunization practices has also planned to cast its opinion regarding Shringrix.

Most analysts, it is reported, have been expecting a positive affirmation on Shringrix from the advisory committee, so that it can be liberally used for older adults. The expectation specifically borders on the fact that the elderly are more vulnerable to shingles and chicken pox owing to the recurrence of the varicella-zoster virus among older people.

For the record, GSK has also secured recommendation from the UK cost authorities to carry out a USD 700,000 worth gene therapy over the ‘bubble boy’ disease.



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Digital Signal Processors (DSP) Market 2021-2026 Detailed Analysis and Growth Strategies, Regional and Recent Scenario Analysis

Author: Ashwin Naphade

Decoding Covid-19 impact on Digital Signal Processors (DSP) market over 2021-2026, with report inclusions as growth determinants, challenges, and revenue generating prospects.

The latest Digital Signal Processors (DSP) market report is a...


Digital Photography Market by Latest Trend, Growing Demand and Technology Advancement 2021-2026

Author: Ashwin Naphade

An elaborative documentation of Digital Photography market dynamics over 2021-2026 unveils the profitable prospects dormant in the business sphere, while emphasizing on Covid-19 impact.

The latest Digital Photography market report is a d...


New Trends in Digital Patient Monitoring Devices Market Size 2021 | Methodology, Estimation, Research and Future Growth by 2026

Author: Ashwin Naphade

Digital Patient Monitoring Devices market report thoroughly expounds on the contingencies created by Covid-19 pandemic in micro-market across regions, and how this governs the overall growth matrix.

The latest Digital Patient Monitoring ...